.jpg)
Neurotech nabs FDA approval to treat rare eye disorder with cell therapy implant Encelto
The FDA last week approved Neurotech’s cell therapy implant revakinagene taroretcel to treat the vision-robbing neurodegenerative disease macular telangiectasia type 2. The therapy, which will adopt the brand name Encelto, is the first to win the FDA’s blessing in the rare vision disorder.
The FDA last week approved Neurotech’s cell therapy implant revakinagene taroretcel to treat the vision-robbing neurodegenerative disease macular telangiectasia type 2. The therapy, which will adopt the brand name Encelto, is the first to win the FDA’s blessing in the rare vision disorder.
